Table 3.
Tumor vaccination trials for breast cancer in the recruitment phase
| Agents | Trial / Phase | Setting |
|---|---|---|
| Dendritic cell vaccine (DC1) | HER2-Directed Dendritic Cell Vaccine during Neoadjuvant Therapy of HER2+Breast Cancer / Phase 1 | Neoadjuvant |
| Mammaglobin-A DNA vaccine | Safety and Immune Response to a Mammaglobin-A DNA Vaccine in Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy / Phase 1 | Neoadjuvant |
| PVSRIPO | Examining Bioactivity of PVSRIPO in Invasive Breast Cancer / Phase 1 | Neoadjuvant |
| V3-MOMMO | Open Label Immunotherapy Trial for Breast Cancer / Phase 2 | Neoadjuvant |
| Granulocyte-macrophage colony-stimulating factor, multi-epitope HER2 peptide vaccine H2NVAC | A Vaccine (H2NVAC) before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma in situ / Phase 1 | Neoadjuvant |
| Poly ICLC | Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients with Persistent Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy / Phase 2 | Adjuvant |
| Neo-antigen pulsed dendritic cell | Breast Cancer Neoantigen Vaccination with Autologous Dendritic Cells / Phase 1 | Adjuvant |
| Neoantigen DNA vaccine durvalumab | Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine plus Durvalumab in Triple-Negative Breast Cancer Patients following Standard of Care Therapy / Phase 1 | Adjuvant |
| P10s-PADRE with MONTANIDETM ISA 51 VG | Vaccination of Triple-Negative Breast Cancer Patients / Phase 2 | Adjuvant |
| DC1 vaccine WOKVAC vaccine | Vaccine to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer / Phase 2 | Adjuvant |
| Cyclophosphamide Multi-epitope folate receptor-α peptide vaccine | Multi-Epitope Folate Receptor-α Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients with Triple-Negative Breast Cancer / Phase 2 | Adjuvant |
| Typhoid vaccine | Typhoid Vaccine in Testing Response to Immune Stress in Patients with Stage I-IIIA Breast Cancer | Adjuvant |
| Pertuzumab Sargramostim | TPIV100 and Sargramostim for the Treatment of HER2-Positive, Stage II-III Breast Cancer in Patients with Residual Disease after Chemotherapy and Surgery / Phase 2 | Adjuvant |
| Activated CIK and CD3-MUC1 bispecific antibody cryotherapy | Study of Activated Cytokine-Induced Killer Armed with Bispecific Antibody for Advanced Breast Cancer / Phase 2 | Adjuvant |
| YE-NEO-001 | QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine to Induce T-Cell Responses in Subjects w/ Previously Treated Cancers / Phase 1 | Adjuvant |
| CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine | Vaccine Therapy in Treating Patients with HER2-Negative Stage III-IV Breast Cancer / Phase 1 | Adjuvant/ metastatic |
| HER2 DC1 vaccine | Immune Response and Potential Booster for Patients Who Have Received HER2-Pulsed DC1 / Phase 2 | Adjuvant/ metastatic |
| HER-2 vaccine | Vaccine Therapy in Treating Patients with Metastatic Solid Tumors / Phase 1 | Adjuvant/ metastatic |
| VRP-HER2 Pembrolizumab | A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients with Breast Cancer / Phase 2 | Metastatic |
| AE37 peptide vaccine Pembrolizumab | Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination with Pembrolizumab that Will Enhance the Tumor-Specific Immune Response and Demonstrate Efficacy in Patients with Advanced Triple-Negative Breast Cancer / Phase 2 | Metastatic |
| PVX-410 pembrolizumab | PVX-410 Vaccine plus Pembrolizumab in HLA-A2+ Metastatic Triple-Negative Breast Cancer / Phase 1 | Metastatic |
| PF-06936308 | A Study to Evaluate Escalating Doses of a Vaccine-Based Immunotherapy Regimen for NSCLC and TNBC / Phase 1 | Metastatic |
| SV-BR-1-GM INCMGA00012 Cyclophosphamide | Combination Study of SV-BR-1-GM in Combination with INCMGA00012 and Epacadostat / Phases 1 and 2 | Metastatic |
| Pembrolizumab Flt3L Poly ICLC |
Vaccination with Flt3L, Radiation, and Poly-ICLC / Phases 1 and 2 | Metastatic |
| Galinpepimut-S Pembrolizumab | Galinpepimut-S in Combination with Pembrolizumab in Patients with Selected Advanced Cancers / Phases 1 and 2 | Metastatic |
| ARG1-18,19,20 | Arginase-1 Peptide Vaccine in Patients with Metastatic Solid Tumors / Phase 1 | Metastatic |
| Durvalumab Tremelimumab Poly ICLC | A Phase 1/2 Study of in situ Vaccination with Tremelimumab and IV Durvalumab plus PolyICLC in Subjects with Advanced, Measurable, Biopsy-Accessible Cancers / Phase 1 and 2 | Metastatic |
| Autologous or allogeneic tumor cells | Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors / Phases 1 and 2 | Metastatic |
| RO7198457 Atezolizumab | A Study of RO7198457 as a Single Agent and in Combination with Atezolizumab in Participants with Locally Advanced or Metastatic Tumors / Phase 1 | Metastatic |